The global drug discovery outsourcing market size is calculated at USD 4.45 billion in 2025 and is forecasted to reach around USD 8.43 billion by 2034, accelerating at a CAGR of 7.34% from 2025 to 2034. The North America drug discovery outsourcing market size surpassed USD 1.46 billion in 2024 and is expanding at a CAGR of 7.36% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug Discovery Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug Discovery Outsourcing Market, by Workflow Type,
8.1.1. Target Identification & Screening
8.1.1.1. Market Revenue and Forecast
8.1.2. Lead Identification & Candidate Optimization
8.1.2.1. Market Revenue and Forecast
8.1.3. Target Validation & Functional Informatics
8.1.3.1. Market Revenue and Forecast
8.1.4. Preclinical Development
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Drug Discovery Outsourcing Market, by Therapeutic Area,
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Cardiovascular
9.1.2.1. Market Revenue and Forecast
9.1.3. Gastrointestinal
9.1.3.1. Market Revenue and Forecast
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast
9.1.5. Respiratory
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Drug Discovery Outsourcing Market, by Drug Type,
10.1.1. Biologics
10.1.1.1. Market Revenue and Forecast
10.1.2. Small Molecules
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Workflow
11.1.2. Market Revenue and Forecast, by Therapeutic Area
11.1.3. Market Revenue and Forecast, by Drug Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Workflow
11.1.4.2. Market Revenue and Forecast, by Therapeutic Area
11.1.4.3. Market Revenue and Forecast, by Drug Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Workflow
11.1.5.2. Market Revenue and Forecast, by Therapeutic Area
11.1.5.3. Market Revenue and Forecast, by Drug Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Workflow
11.2.2. Market Revenue and Forecast, by Therapeutic Area
11.2.3. Market Revenue and Forecast, by Drug Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Workflow
11.2.4.2. Market Revenue and Forecast, by Therapeutic Area
11.2.4.3. Market Revenue and Forecast, by Drug Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Workflow
11.2.5.2. Market Revenue and Forecast, by Therapeutic Area
11.2.5.3. Market Revenue and Forecast, by Drug Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Workflow
11.2.6.2. Market Revenue and Forecast, by Therapeutic Area
11.2.6.3. Market Revenue and Forecast, by Drug Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Workflow
11.2.7.2. Market Revenue and Forecast, by Therapeutic Area
11.2.7.3. Market Revenue and Forecast, by Drug Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Workflow
11.3.2. Market Revenue and Forecast, by Therapeutic Area
11.3.3. Market Revenue and Forecast, by Drug Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Workflow
11.3.4.2. Market Revenue and Forecast, by Therapeutic Area
11.3.4.3. Market Revenue and Forecast, by Drug Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Workflow
11.3.5.2. Market Revenue and Forecast, by Therapeutic Area
11.3.5.3. Market Revenue and Forecast, by Drug Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Workflow
11.3.6.2. Market Revenue and Forecast, by Therapeutic Area
11.3.6.3. Market Revenue and Forecast, by Drug Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Workflow
11.3.7.2. Market Revenue and Forecast, by Therapeutic Area
11.3.7.3. Market Revenue and Forecast, by Drug Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Workflow
11.4.2. Market Revenue and Forecast, by Therapeutic Area
11.4.3. Market Revenue and Forecast, by Drug Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Workflow
11.4.4.2. Market Revenue and Forecast, by Therapeutic Area
11.4.4.3. Market Revenue and Forecast, by Drug Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Workflow
11.4.5.2. Market Revenue and Forecast, by Therapeutic Area
11.4.5.3. Market Revenue and Forecast, by Drug Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Workflow
11.4.6.2. Market Revenue and Forecast, by Therapeutic Area
11.4.6.3. Market Revenue and Forecast, by Drug Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Workflow
11.4.7.2. Market Revenue and Forecast, by Therapeutic Area
11.4.7.3. Market Revenue and Forecast, by Drug Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Workflow
11.5.2. Market Revenue and Forecast, by Therapeutic Area
11.5.3. Market Revenue and Forecast, by Drug Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Workflow
11.5.4.2. Market Revenue and Forecast, by Therapeutic Area
11.5.4.3. Market Revenue and Forecast, by Drug Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Workflow
11.5.5.2. Market Revenue and Forecast, by Therapeutic Area
11.5.5.3. Market Revenue and Forecast, by Drug Type
12.1. Albany Molecular Research Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. EVOTEC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Laboratory Corporation of America Holdings
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GenScript
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pharmaceutical Product Development, LLC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Charles River
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WuXiAppTec
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Thermo Fisher Scientific Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Dalton Pharma Services
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Oncodesign
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Jubilant Biosys
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. DiscoverX Corporation
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample